Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Obstetrics and Gynecology

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajog.2011.12.028PMID 22301440PMCID PMC3987114
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass

  2011cited by this paper
• HE4: a new potential early biomarker for the recurrence of ovarian cancer

  2010cited by this paper
• Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

  2010cited by this paper
• Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass

  2010cited by this paper
• Current state of biomarker development for clinical application in epithelial ovarian cancer.

  2010cited by this paper
• Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

  2009cited by this paper
• Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

  2009cited by this paper
• Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

  2009cited by this paper
• A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

  2009cited by this paper
• Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer

  2008cited by this paper
• Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women

  2008cited by this paper
• The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

  2008cited by this paper
• Tumor Markers In Biological Fluids Associated With Pregnancy

  2007cited by this paper
• Comprehensive analysis of HE4 expression in normal and malignant human tissues

  2006cited by this paper
• Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

  2005cited by this paper
• Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

  2005cited by this paper
• New tumor markers: CA125 and beyond

  2005cited by this paper
• CA 125 in the serum and tissue of patients with gynecological disease

  2004cited by this paper
• Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.

  2003cited by this paper
• The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

  2003cited by this paper
• Factors influencing serum CA125II levels in healthy postmenopausal women.

  2001cited by this paper
• Benign conditions associated with raised serum CA‐125 concentration

  2000cited by this paper
• CA 125 in Benign Gynecological Conditions

  1998cited by this paper
• Serum CA 125 concentrations in patients with benign ovarian tumours

  1994cited by this paper
• Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line.

  1993cited by this paper
• Increased Serum Ca 125 Levels During the First Trimester of Pregnancy

  1986cited by this paper
• CA125 Antigen Levels in Obstetric and Gynecologic Patients

  1984cited by this paper
• A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

  1983cited by this paper
• Reactivity of a monoclonal antibody with human ovarian carcinoma.

  1981cited by this paper
• American journal of obstetrics & gynecology

  year unknowncited by this paper

• Diagnostic Performance of ROMA and Biomarkers in Ovarian Cancer: A Systematic Review of Sensitivity, Specificity, and Menopausal Influence

  2026cites this paper
• Simpler predictive models provide higher accuracy for ovarian cancer detection

  2025cites this paper
• Application of Extracellular Vesicle Exosomes in Epithelial Ovarian Cancer

  2025cites this paper
• Reference values of human epididymis protein 4 in the Bulgarian population - assessment of the influence of age, menopause, pregnancy, and renal function.

  2025cites this paper
• Ovarian Cysts and Pregnancy: What is New? A Literature Review

  2025cites this paper
• The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation

  2024cites this paper
• Human epididymis protein 4: Analysis of national health and nutrition examination survey data.

  2024cites this paper
• Tumor biomarkers HE4 and CA125 alongside enhanced computed tomography imaging in assessing lymph node metastasis in endometrial cancer

  2024cites this paper
• Development and Validation of a Model Predicting Malignant Potential of Adnexal Masses in Areas with Scarcity of Ultrasound Resources

  2024cites this paper
• Diagnostic role of urine human epididymis protein 4 in ovarian cancer

  2024cites this paper
• Development and validation of a novel combinational index of liquid biopsy biomarker for longitudinal lung cancer patient management

  2024cites this paper
• Advancements in Gynecology: A Comprehensive Review of Emerging Research and Innovations

  2024cites this paper
• Cáncer y embarazo

  2023cites this paper
• Extrauterine adenomyoma: A case report and systematic review of the literature

  2023cites this paper
• HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review

  2022cites this paper
• Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features

  2022cites this paper
• Circular RNAs in Epithelial Ovarian Cancer: From Biomarkers to Therapeutic Targets

  2022cites this paper
• Nanomaterial-based biosensor developing as a route toward in vitro diagnosis of early ovarian cancer

  2022cites this paper
• Impedimetric immunosensors for detection of biomarkers

  2022cites this paper
• Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors

  2022cites this paper
• Cancers et grossesse

  2022cites this paper
• Effect of Serum Level of Human Epididymis Protein 4 and Interleukin-6 as Biomarkers in Patients with Adnexal Mass.

  2022cites this paper
• Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer

  2022cites this paper
• Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?

  2022cites this paper
• The Association between Human Epididymis Secretory Protein 4 and Metabolic Syndrome

  2022cites this paper
• Exploring the relationship between preeclampsia and human epididymis protein 4

  2022cites this paper
• Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers

  2022cites this paper
• Comparative assessment of RMI-IV and RMI-V in preoperative prediction of ovarian tumor type in pregnant women

  2022cites this paper
• Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics

  2021cites this paper
• Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).

  2021influential citation
• CMAR_A_290592 2329..2339

  2021cites this paper
• Current clinical application of serum biomarkers to detect and monitor ovarian cancer – update

  2021influential citation
• Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.

  2021cites this paper
• Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

  2021cites this paper
• Evaluation of efficacy and safety of vertebroplasty in the treatment of osteoporotic vertebral compression fracture

  2021cites this paper
• HE4 as a Biomarker for Endometrial Cancer

  2021cites this paper
• Exploration of Potential Diagnostic Value of Protein Content in Serum Small Extracellular Vesicles for Early-Stage Epithelial Ovarian Carcinoma

  2021cites this paper
• Influence of Pregnancy-Related Conditions on Human Epididymis Protein 4 Serum Levels in Comparison to CA 125 – a Prospective Cohort Trial

  2021cites this paper
• Management of colorectal cancer during pregnancy Manejo del cáncer colorrectal durante el embarazo

  2021cites this paper
• Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review

  2021cites this paper
• The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta‐analysis

  2021cites this paper
• Diagnostic value of serum human epididymis protein 4 and cancer antigen 125 in the patients with ovarian carcinoma

  2021cites this paper
• May human epididymis 4 protein play a role in the etiopathogenesis of hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome?

  2021cites this paper
• Approaches to the Diagnosis and Management of Ovarian Cancer in Pregnancy

  2021cites this paper
• Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early-stage ovarian cancer according to imaging tumor subtypes.

  2020cites this paper
• Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people

  2020influential citation
• Pathology of Peritoneal Metastases: The Unchartered Fields

  2020cites this paper
• Ovarian cysts in pregnancy: a narrative review

  2020cites this paper
• [Borderline ovarian tumours: CNGOF Guidelines for clinical practice - Pregnancy].

  2020cites this paper
• Serum concentrations of HE4 and Ca125 in uncomplicated pregnancies: a longitudinal study

  2020cites this paper
• Manejo del cáncer de ovario durante el embarazo

  2020cites this paper
• Serum HE4 as a prognostic marker in cervical cancer: a retrospective study

  2020cites this paper
• HE4 and Ovarian Cancers: New Era of Diagnosis

  2020cites this paper
• HE4 levels in uncomplicated pregnancies: are there any differences?

  2020cites this paper
• CLINICAL APPLICATION OF NOVEL CIRCULATORY BIOMARKERS IN EPITHELIAL OVARIAN CANCER

  2020cites this paper
• HE4 in Various Body Fluids: A Prospective Pilot Study

  2020cites this paper
• Biomarkers in the Management of Peritoneal Metastases

  2020cites this paper
• Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.

  2020cites this paper
• Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women

  2020cites this paper
• Clinical implementation of novel diagnostic biomarkers for epithelial ovarian cancer - Can we improve diagnosis?

  2020cites this paper
• Dif f iculties with diagnosis of malignancies in pregnancy

  2019cites this paper
• [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].

  2019cites this paper
• Prognostic molecular biomarkers in endometrial cancer: A review

  2019cites this paper
• Preoperative Evaluation of Ovarian Tumors

  2019cites this paper
• Enhanced electrochemiluminescence of luminol-DBAE system based on self-assembled mesocrystalline hybrid for the detection of ovarian cancer marker

  2019cites this paper
• Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review

  2019cites this paper
• Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial

  2019cites this paper
• Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.

  2019cites this paper
• Role of Tumor Markers

  2019cites this paper
• The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4

  2019cites this paper
• Biomarkers of Gynecological Cancers

  2019cites this paper
• CA125, YKL-40, HE-4 and Mesothelin: a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor

  2019cites this paper
• Clinical biomarkers for detection of ovarian cancer

  2019cites this paper
• USPOREDBA KONCENTRACIJE SALIVARNOGA I SERUMSKOGA CA125 U BOLESNICA S BENIGNIM I MALIGNIM TUMORIMA JAJNIKA

  2019cites this paper
• Sensitive amperometric immunosensor with improved electrocatalytic Au@Pd urchin-shaped nanostructures for human epididymis specific protein 4 antigen detection.

  2019cites this paper
• Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors

  2019cites this paper
• CA 125 , YKL-40 , HE-4 and Mesothelin : a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor CA 125 , YKL-40 , HE-4 ve Mezotelin : Benign ve Malign Epitelial

  2019cites this paper
• Gynecologic Etiologies of Abdominal Pain in Pregnancy

  2018cites this paper
• Serum levels of human epididymis protein 4 are more stable than cancer antigen 125 in early and mid‐term pregnancy

  2018cites this paper
• Making new biomarkers a reality: the case of serum human epididymis protein 4

  2018cites this paper
• Pia Suvitie: Modern methods of evaluating endometriosis

  2018cites this paper
• Cancer in pregnancy

  2018cites this paper
• Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women

  2018cites this paper
• Current approaches in the clinical management of pregnancy-associated breast cancer—pros and cons

  2018cites this paper
• Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors

  2018cites this paper
• The Use of HE-4 in Gynecological Cancers

  2018influential citation
• The Complementary Role of Imaging and Tumor Biomarkers in Gynecological Cancers: An Update of the Literature

  2018influential citation
• Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.

  2018cites this paper
• Intérêt du dosage de l’HE4 et du score ROMA dans le diagnostic de l’endométriose

  2018cites this paper
• Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?

  2018cites this paper
• Determination of the Reference Values of the Tumor Marker HE4 in Female Population of Canton Sarajevo

  2018cites this paper
• The Clearance of Serum Human Epididymis Protein 4 Following Primary Cytoreductive Surgery for Ovarian Carcinoma

  2018cites this paper
• Improving performance for classifying ovarian cancer with menopause information

  2018cites this paper
• Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer

  2017cites this paper
• Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City

  2017cites this paper
• Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer

  2017cites this paper
• Tuulia Vallius: NOVEL PREDICTORS OF RESPONSE AND OUTCOME IN ADVANCED EPITHELIAL OVARIAN CANCER

  2017cites this paper
• Reply to comment of Prof. Artur Czekierdowski

  2017cites this paper
• MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer

  2017cites this paper
• Syddansk Universitet Adjustment of serum HE 4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer

  2017cites this paper